PMID- 27496505
OWN - NLM
STAT- MEDLINE
DCOM- 20170426
LR  - 20211204
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 48
IP  - 5
DP  - 2016 Jun
TI  - Kaposi Sarcoma in the Genital Area in a Kidney Transplant Patient: A Case Report 
      and Literature Review.
PG  - 1843-8
LID - S0041-1345(16)00329-8 [pii]
LID - 10.1016/j.transproceed.2016.01.070 [doi]
AB  - BACKGROUND: Kaposi sarcoma (KS) is a cancer with an incidence in patients after 
      transplantation (Tx) that is 500 times greater than that in the healthy 
      population. The risk of KS increases significantly during therapy, especially 
      when immunosuppressive therapy with cyclosporine A (CsA) is used. Most cases of 
      KS develop during the first 2 years after transplantation. After a KS diagnosis, 
      it is recommended to reduce the doses of immunosuppressive medications. 
      Conversion of immunosuppressive treatment into mammalian target of rapamycin 
      (m-TOR) inhibitors is strongly suggested. PATIENTS AND METHODS: We present the 
      case of a 65-year-old man with end-stage renal disease (ESRD) of unknown 
      etiology, who had kidney transplantation in 2008. Immunosuppressive protocol was 
      based on CsA, mycophenolate mofetil (MMF) and prednisolone (PRE). In 2011, during 
      the dermatological consultation, on the penis glans a purple stain of uneven 
      surface was noted. Histology study revealed the presence of KS. The treatment was 
      modified. The patient was converted from CsA to everolimus. Before converting, 
      the creatinine concentration was 1.79 mg/dl and proteinuria less than 0.3 g/day. 
      RESULTS: The change in the scheme of immunosuppresion from CsA to everolimus was 
      performed to treat the Kaposi sarcoma. Gradually, within a year, the KS was 
      cured. However, the graft function deteriorated, and the graft was lost in 
      one-years' time. CONCLUSION: We present the first documented case of KS in the 
      genital area of a kidney patient. The reduction in the strength of 
      immunosuppression, and the introduction of an m-TOR inhibitor, may have 
      contributed to the deterioration of kidney function, however it was substantial 
      in the treatment of KS.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Imko-Walczuk, B
AU  - Imko-Walczuk B
AD  - Copernicus-Independent Public Healthcare Centre, Dermatology & Venereology 
      Clinic, Gdansk, Poland; College of Health, Beauty and Education in Poznan, 
      Poland. Electronic address: bimko@wp.pl.
FAU - Kielbowicz, M
AU  - Kielbowicz M
AD  - College of Health, Beauty and Education in Poznan, Poland.
FAU - Malyszko, J
AU  - Malyszko J
AD  - 1st Department of Nephrology and Transplantology with Dialysis Unit, Medical 
      University, Bialystok, Poland.
FAU - Malyszko, J
AU  - Malyszko J
AD  - 2nd Department of Nephrology Medical University, Bialystok, Poland.
FAU - Barczyk, M
AU  - Barczyk M
AD  - 1st Department of Nephrology and Transplantology with Dialysis Unit, Medical 
      University, Bialystok, Poland.
FAU - Debska-Slizien, A
AU  - Debska-Slizien A
AD  - Chair & Clinic of Nephrology, Transplantology and Internal Medicine, Gdansk 
      University of Medical Sciences, Gdansk, Poland.
FAU - Mysliwiec, M
AU  - Mysliwiec M
AD  - 1st Department of Nephrology and Transplantology with Dialysis Unit, Medical 
      University, Bialystok, Poland.
FAU - Rutkowski, B
AU  - Rutkowski B
AD  - Chair & Clinic of Nephrology, Transplantology and Internal Medicine, Gdansk 
      University of Medical Sciences, Gdansk, Poland.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - 9HW64Q8G6G (Everolimus)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Aged
MH  - Cyclosporine/adverse effects
MH  - Everolimus/*therapeutic use
MH  - Female
MH  - Humans
MH  - *Immunocompromised Host
MH  - Immunosuppression Therapy/adverse effects
MH  - Immunosuppressive Agents/therapeutic use
MH  - Kidney Transplantation/*adverse effects
MH  - Male
MH  - Mycophenolic Acid/adverse effects
MH  - Penile Neoplasms/*immunology
MH  - Prednisolone/therapeutic use
MH  - Sarcoma, Kaposi/*immunology
EDAT- 2016/08/09 06:00
MHDA- 2017/04/27 06:00
CRDT- 2016/08/07 06:00
PHST- 2015/11/29 00:00 [received]
PHST- 2016/01/21 00:00 [accepted]
PHST- 2016/08/07 06:00 [entrez]
PHST- 2016/08/09 06:00 [pubmed]
PHST- 2017/04/27 06:00 [medline]
AID - S0041-1345(16)00329-8 [pii]
AID - 10.1016/j.transproceed.2016.01.070 [doi]
PST - ppublish
SO  - Transplant Proc. 2016 Jun;48(5):1843-8. doi: 10.1016/j.transproceed.2016.01.070.